Dostarlimab

From Wikipedia, the free encyclopedia

Dostarlimab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetPCDP1
Clinical data
Trade namesJemperli
Other namesTSR-042, WBP-285, dostarlimab-gxly
License data
Routes of
administration		Intravenous
Drug classAntineoplastic
ATC code
Legal status
Legal status
Identifiers
CAS Number
  • 2022215-59-2
PubChem SID
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC6420H9832N1690O2014S44
Molar mass144325.73 g·mol−1

Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as a medication for the treatment of endometrial cancer.[1][2][4][5]

The most common side effects reported in the US include fatigue/asthenia, nausea, diarrhea, anemia, and constipation.[1][2] Additional common side effects reported in the EU include vomiting, joint pain, itching, rash, fever, and hypothyroidism (low levels of thyroid hormones).[3]

Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.[1][2][3]

Dostarlimab was approved for medical use in the United States and in the European Union in April 2021.[1][2][6][3][7][8]

Medical uses[]

Dostarlimab is indicated for the treatment of adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.[1][2][3]

On August 17, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dostarlimab for adults with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.[9][10]

Side effects[]

Serious adverse reactions in >2% of patients included sepsis, acute kidney injury, urinary tract infection, abdominal pain, and pyrexia.[1][2]

Immune-mediated adverse reactions can occur including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis.[1][2]

History[]

It is a PD-1 inhibitor. As of 2020, it is undergoing Phase I/II and Phase III clinical trials.[11][12][13] The manufacturer, Tesaro, announced prelimary successful results from the Phase I/II GARNET study.[11][14][15]

In 2020, the GARNET study announced that dostarlimab was demonstrating potential to treat a subset of women with recurrent or advanced endometrial cancer.[16]

April 2021, dostarlimab is approved for the treatment of recurrent or advanced endometrial cancer with deficient mismatch repair (dMMR), which are genetic anomalies abnormalities that disrupt DNA repair.[17]

On April 22, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC).[1] Efficacy was evaluated based on cohort (A1) in GARNET Trial (NCT02715284), a multicenter, multicohort, open-label trial in participants with advanced solid tumors.[1]

Society and culture[]

Legal status[]

On 25 February 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Jemperli, intended for the treatment of certain types of recurrent or advanced endometrial cancer.[18] The applicant for this medicinal product is GlaxoSmithKline (Ireland) Limited.[18] Dostarlimab was approved for medical use in the European Union in April 2021.[3]

References[]

  1. ^ Jump up to: a b c d e f g h i j "FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer". U.S. Food and Drug Administration (FDA) (Press release). 22 April 2021. Retrieved 22 April 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  2. ^ Jump up to: a b c d e f g h "Jemperli- dostarlimab injection". DailyMed. Retrieved 28 April 2021.
  3. ^ Jump up to: a b c d e f "Jemperli EPAR". European Medicines Agency (EMA). 24 February 2021. Retrieved 16 July 2021.
  4. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Dostarlimab, American Medical Association.
  5. ^ World Health Organization (2018). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 119" (PDF). WHO Drug Information. 32 (2).
  6. ^ "FDA grants accelerated approval for GSK's Jemperli (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer" (Press release). GlaxoSmithKline. 22 April 2021. Retrieved 22 April 2021 – via PR Newswire.
  7. ^ "European Commission Approves Jemperli (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe" (Press release). AnaptysBio Inc. 23 April 2021. Retrieved 13 July 2021 – via GlobeNewswire.
  8. ^ "FDA Approves Jemperli (dostarlimab-gxly) for dMMR Endometrial Cancer" (Press release). AnaptysBio, Inc. 22 April 2021. Retrieved 18 August 2021.
  9. ^ "FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors". U.S. Food and Drug Administration (FDA). 18 August 2021. Retrieved 18 August 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  10. ^ "GSK receives FDA accelerated approval for Jemperli (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors". GlaxoSmithKline (Press release). 17 August 2021. Retrieved 18 August 2021.
  11. ^ Jump up to: a b Clinical trial number NCT02715284 for "A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET)" at ClinicalTrials.gov
  12. ^ Clinical trial number NCT03981796 for "A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)" at ClinicalTrials.gov
  13. ^ Clinical trial number NCT03602859 for "A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)" at ClinicalTrials.gov
  14. ^ "Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer". Tesaro (Press release). Retrieved 1 January 2020.
  15. ^ Scalea B (28 May 2019). "Dostarlimab Effective in Endometrial Cancer Regardless of MSI Status". Targeted Oncology. Retrieved 1 January 2020.
  16. ^ "GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer - Drugs.com MedNews". Drugs.com. Retrieved 29 April 2020.
  17. ^ "FDA Approves New Immunotherapy for Endometrial Cancer". Medscape. Retrieved 23 April 2021.
  18. ^ Jump up to: a b "Jemperli: Pending EC decision". European Medicines Agency (EMA) (Press release). 25 February 2021. Retrieved 22 April 2021.

External links[]

  • "Dostarlimab". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT02715284 for "Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (GARNET)" at ClinicalTrials.gov


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""